Compounds > 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)
Page last updated: 2024-09-03

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and Bone Neoplasms

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) has been researched along with Bone Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chakraborty, S; Chakravarty, R; Dash, A; Kamaleshwaran, K; Radhakrishnan, E; Rajeswari, A; Sarma, HD; Shinto, AS; Vimalnath, KV1
Afarideh, H; Bagheri, R; Maragheh, MG; Samani, AB; Shirmardi, SP1
Chuttani, K; Datta, A; Mishra, AK; Panwar, P1
Booser, D; Champlin, RE; de Souza, JA; Hortobagyi, GN; Madewell, J; Nakayama, K; Podoloff, D; Ueno, NT; Wendt, RE1
Banerjee, S; Chakraborty, S; Das, T; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Venkatesh, M1
Breitz, HB; Delpassand, E; Durack, L; Eary, JF; Erwin, WD; Martin, W; Meredith, RF; Rajendran, JG; Shen, S; Stabin, MS; Wendt, RE1

Trials

1 trial(s) available for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and Bone Neoplasms

ArticleYear
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:3

    Topics: Aged; Body Burden; Bone Neoplasms; Female; Holmium; Humans; Male; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radiotherapy Dosage; Relative Biological Effectiveness; Reproducibility of Results; Sensitivity and Specificity; Whole-Body Counting

2006

Other Studies

5 other study(ies) available for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) and Bone Neoplasms

ArticleYear
A "mix-and-use" approach for formulation of human clinical doses of
    Journal of labelled compounds & radiopharmaceuticals, 2017, Volume: 60, Issue:9

    Topics: Animals; Bone Neoplasms; Cancer Pain; Durapatite; Humans; Lutetium; Male; Organophosphorus Compounds; Pharmacy Service, Hospital; Radioisotopes; Rats; Tissue Distribution

2017
Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data.
    Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:4

    Topics: Bone Marrow; Bone Neoplasms; Etidronic Acid; Femur; Humans; Organophosphorus Compounds; Radiation Dosage; Radiopharmaceuticals

2015
Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases.
    Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:1

    Topics: Animals; Bone Neoplasms; Chelating Agents; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Organophosphorus Compounds; Rabbits; Radionuclide Imaging; Radiopharmaceuticals; Rats; Technetium; Time Factors; Tissue Distribution

2009
Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.
    Clinical breast cancer, 2009, Volume: 9, Issue:3

    Topics: Adult; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Organophosphorus Compounds; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Treatment Outcome

2009
177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2002, Volume: 57, Issue:2

    Topics: Animals; Bone Neoplasms; Heterocyclic Compounds, 1-Ring; Lutetium; Organophosphonates; Organophosphorus Compounds; Pain; Palliative Care; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution

2002